414 related articles for article (PubMed ID: 26622168)
1. Apatinib for molecular targeted therapy in tumor.
Zhang H
Drug Des Devel Ther; 2015; 9():6075-81. PubMed ID: 26622168
[TBL] [Abstract][Full Text] [Related]
2. Apatinib for the treatment of gastric cancer.
Roviello G; Ravelli A; Fiaschi AI; Cappelletti MR; Gobbi A; Senti C; Zanotti L; Polom K; Reynolds AR; Fox SB; Generali D
Expert Rev Gastroenterol Hepatol; 2016 Aug; 10(8):887-92. PubMed ID: 27376400
[TBL] [Abstract][Full Text] [Related]
3. Apatinib: a promising oral antiangiogenic agent in the treatment of multiple solid tumors.
Scott AJ; Messersmith WA; Jimeno A
Drugs Today (Barc); 2015 Apr; 51(4):223-9. PubMed ID: 26020064
[TBL] [Abstract][Full Text] [Related]
4. Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer.
Roviello G; Ravelli A; Polom K; Petrioli R; Marano L; Marrelli D; Roviello F; Generali D
Cancer Lett; 2016 Mar; 372(2):187-91. PubMed ID: 26797419
[TBL] [Abstract][Full Text] [Related]
5. Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers.
Scott LJ
Drugs; 2018 May; 78(7):747-758. PubMed ID: 29663291
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic potentials of Apatinib in cancer treatment: Possible mechanisms and clinical relevance.
Fathi Maroufi N; Rashidi MR; Vahedian V; Akbarzadeh M; Fattahi A; Nouri M
Life Sci; 2020 Jan; 241():117106. PubMed ID: 31786193
[TBL] [Abstract][Full Text] [Related]
7. Angiogenesis and apatinib: Can be used for the patients with non-gastic cancer?
Ni Y; Ye X
J Cancer Res Ther; 2018; 14(4):727-729. PubMed ID: 29970645
[No Abstract] [Full Text] [Related]
8. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
[TBL] [Abstract][Full Text] [Related]
9. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
10. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
Amino N; Ideyama Y; Yamano M; Kuromitsu S; Tajinda K; Samizu K; Hisamichi H; Matsuhisa A; Shirasuna K; Kudoh M; Shibasaki M
Clin Cancer Res; 2006 Mar; 12(5):1630-8. PubMed ID: 16533791
[TBL] [Abstract][Full Text] [Related]
11. Apatinib for the treatment of gastric cancer.
Geng R; Li J
Expert Opin Pharmacother; 2015 Jan; 16(1):117-22. PubMed ID: 25420417
[TBL] [Abstract][Full Text] [Related]
12. Phosphorylated VEGFR2 and hypertension: potential biomarkers to indicate VEGF-dependency of advanced breast cancer in anti-angiogenic therapy.
Fan M; Zhang J; Wang Z; Wang B; Zhang Q; Zheng C; Li T; Ni C; Wu Z; Shao Z; Hu X
Breast Cancer Res Treat; 2014 Jan; 143(1):141-51. PubMed ID: 24292957
[TBL] [Abstract][Full Text] [Related]
13. Apatinib-induced hyperammonemic encephalopathy.
Liu Y; Chen X; Gao X; Chen JX; Chen J
J Oncol Pharm Pract; 2020 Mar; 26(2):465-470. PubMed ID: 31068089
[TBL] [Abstract][Full Text] [Related]
14. Angiogenesis and apatinib: a new hope for patients with advanced gastric cancer?
de Mello RA; de Oliveira J; Antoniou G
Future Oncol; 2017 Feb; 13(4):295-298. PubMed ID: 27928929
[No Abstract] [Full Text] [Related]
15. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
Grothey A; Ellis LM
Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
[TBL] [Abstract][Full Text] [Related]
16. The Sabotaging Role of Myeloid Cells in Anti-Angiogenic Therapy: Coordination of Angiogenesis and Immune Suppression by Hypoxia.
Li C; Liu T; Bazhin AV; Yang Y
J Cell Physiol; 2017 Sep; 232(9):2312-2322. PubMed ID: 27935039
[TBL] [Abstract][Full Text] [Related]
17. Apatinib as targeted therapy for advanced bone and soft tissue sarcoma: a dilemma of reversing multidrug resistance while suffering drug resistance itself.
Yang QK; Chen T; Wang SQ; Zhang XJ; Yao ZX
Angiogenesis; 2020 Aug; 23(3):279-298. PubMed ID: 32333216
[TBL] [Abstract][Full Text] [Related]
18. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous determination of apatinib and its four major metabolites in human plasma using liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study.
Ding J; Chen X; Dai X; Zhong D
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 May; 895-896():108-15. PubMed ID: 22503745
[TBL] [Abstract][Full Text] [Related]
20. Anacardic acid (6-pentadecylsalicylic acid) inhibits tumor angiogenesis by targeting Src/FAK/Rho GTPases signaling pathway.
Wu Y; He L; Zhang L; Chen J; Yi Z; Zhang J; Liu M; Pang X
J Pharmacol Exp Ther; 2011 Nov; 339(2):403-11. PubMed ID: 21828260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
